Skip to content
Screener

OnKure Therapeutics, Inc. OKUR Total Revenue

Discontinued — last reported Q4 '24

Total Revenue at other companies

Pfizer logo
PfizerPFE
$15.03B+2.6%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$0-100%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$6.56M—
Arcus Biosciences logo
Arcus BiosciencesRCUS
$41M-74.4%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$0-100%
BillionToOne, Inc. logo
BillionToOne, Inc.BLLN
$109.45M+64.4%

Other financials

Income statement

See full
Operating income-$15.6M+8.1%
Net income-$15.2M+4.8%
EPS (diluted)-$1.11+6.7%

Balance sheet

See full
Cash & equivalents$192.1M+98.7%
Total debt$409.0K-57.2%
Total equity$184.4M+103%
Total assets$198.7M+98.9%

Cash flow

See full
Operating cash flow-$12.9M+7.6%
CapEx$5.0K-72.2%
Free cash flow-$12.9M+7.7%

Valuation

See full
Market cap$153.89M+29.0%
Enterprise value-$37.81M-203%

Returns & leverage

See full
Return on equity-42.7%—
Debt / equity0×0.0×
Current ratio13.8×+2.6×

Where this comes from

Reported directly by OnKure Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: OnKure Therapeutics, Inc.’s 10-K, filed March 10, 2025.

Filed
Mar 10, 2025
Fiscal year
FY2024
Accession
0000950170-25-036252

The clinical research segment has no revenues. The accounting policies of the clinical research segment are the same as those described in the summary of significant accounting policies.

Item 8. Financial Statements and Supplementary Data

FAQ

What is OnKure Therapeutics, Inc.'s total revenue?
OnKure Therapeutics, Inc. (OKUR) reported total revenue of $0 in Q4 2024.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about OnKure Therapeutics, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude